FR2775692B1 - Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre - Google Patents

Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre

Info

Publication number
FR2775692B1
FR2775692B1 FR9802558A FR9802558A FR2775692B1 FR 2775692 B1 FR2775692 B1 FR 2775692B1 FR 9802558 A FR9802558 A FR 9802558A FR 9802558 A FR9802558 A FR 9802558A FR 2775692 B1 FR2775692 B1 FR 2775692B1
Authority
FR
France
Prior art keywords
cells
implementation
methods
natural killer
activating natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9802558A
Other languages
English (en)
Other versions
FR2775692A1 (fr
Inventor
Laurence Zitvogel
Nadine Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Original Assignee
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR) filed Critical Institut Gustave Roussy (IGR)
Priority to FR9802558A priority Critical patent/FR2775692B1/fr
Priority to US09/260,512 priority patent/US6849452B1/en
Priority to CA002322712A priority patent/CA2322712A1/fr
Priority to JP05552899A priority patent/JP3541140B2/ja
Priority to TW088103226A priority patent/TW585915B/zh
Priority to AU32579/99A priority patent/AU758622B2/en
Priority to EP99937940A priority patent/EP1080184A1/fr
Priority to PCT/FR1999/000482 priority patent/WO1999045102A1/fr
Publication of FR2775692A1 publication Critical patent/FR2775692A1/fr
Application granted granted Critical
Publication of FR2775692B1 publication Critical patent/FR2775692B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4613Natural-killer cells [NK or NK-T]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/26Flt-3 ligand (CD135L, flk-2 ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR9802558A 1998-03-03 1998-03-03 Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre Expired - Fee Related FR2775692B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR9802558A FR2775692B1 (fr) 1998-03-03 1998-03-03 Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
US09/260,512 US6849452B1 (en) 1998-03-03 1999-03-02 Methods for activating natural killer (NK) cells and means for carrying out said methods
JP05552899A JP3541140B2 (ja) 1998-03-03 1999-03-03 ナチュラルキラー(nk)細胞の活性化方法及びその実施手段
TW088103226A TW585915B (en) 1998-03-03 1999-03-03 Methods for activating natural killer (NK) cells
CA002322712A CA2322712A1 (fr) 1998-03-03 1999-03-03 Methodes d'activation de cellules tueuses naturelles (nk)
AU32579/99A AU758622B2 (en) 1998-03-03 1999-03-03 Method for activating natural killer (NK) cells
EP99937940A EP1080184A1 (fr) 1998-03-03 1999-03-03 Methodes d'activation de cellules tueuses naturelles (nk)
PCT/FR1999/000482 WO1999045102A1 (fr) 1998-03-03 1999-03-03 Methodes d'activation de cellules tueuses naturelles (nk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9802558A FR2775692B1 (fr) 1998-03-03 1998-03-03 Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre

Publications (2)

Publication Number Publication Date
FR2775692A1 FR2775692A1 (fr) 1999-09-10
FR2775692B1 true FR2775692B1 (fr) 2000-06-16

Family

ID=9523585

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9802558A Expired - Fee Related FR2775692B1 (fr) 1998-03-03 1998-03-03 Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre

Country Status (1)

Country Link
FR (1) FR2775692B1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3619853B2 (ja) * 1999-11-26 2005-02-16 独立行政法人理化学研究所 ナチュラルキラー細胞の増殖方法
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (fr) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Procedes d'utilisation de cellules dendritiques pour activer des lymphocytes t
WO1995034638A1 (fr) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Procedes pour l'activation de lymphocytes t in vivo par des cellules dendritiques a impulsions antigeniques
AU697539B2 (en) * 1995-10-04 1998-10-08 Immunex Corporation Dendritic cell stimulatory factor

Also Published As

Publication number Publication date
FR2775692A1 (fr) 1999-09-10

Similar Documents

Publication Publication Date Title
PL346653A1 (en) Methods, instruments and materials for chondrocyte cell transplantation
DE69737948D1 (de) Vorrichtung zur rekonstruktion von sehnen
NO20001015D0 (no) Cellulosestruktur med forskjellig densitet og fremgangsmõte for fremstilling derav
EP0961824A4 (fr) Procede d'activation de cellules dendritiques
EP1051624A4 (fr) Series haute densite pour l'analyse des proteomes et procedes et compositions pour ces derniers
FR2739028B1 (fr) Dispositif d'encapsulation de cellules ameliore
ZA983540B (en) Method of producing hydrogen using solid electrolyte membrane
DE69931346D1 (de) Vorrichtung zur erzeugung optischer gradientenkräfte
PL336693A1 (en) Novel method of obtaining farmacologically active substances
IL116994A (en) Method of preparing an undifferentiated cell
AU6505299A (en) Methods for generating antigen-reactive t cells (in vitro)
DE69826559D1 (de) Dampferzeugungsverfahren und Vorrichtung zur Durchführung dieses Verfahren
DE69810604D1 (de) Vorrichtung und methode zur gasgeneration
ID21933A (id) Zat untuk penghambatan produksi sitokin dan zat untuk penghambatan adesi sel
EP1109931A4 (fr) PROCEDE D'ETUDE D'INTERACTIONS DE PROTEINES $i(IN VIVO)
DE69606691D1 (de) Silikonhaltige Blockcopolymere
FR2775692B1 (fr) Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
FR2782524B1 (fr) Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
PL337716A1 (en) Method of obtaining thiazafurin and other c-nucleosides
DE69612531D1 (de) Elektrochemische Vorrichtung
IL129094A0 (en) Hematopoietic stem cells and methods for generating such cells
HK1038509A1 (en) Method and system for production and collection oflavage induced stool (lis) for chemical and biolo gic test of cells.
NO951479L (no) Fremgangsmate og anordning ved oppankret fartoy
NO20012667D0 (no) Fremgangsmåte for aktivering av vann og anvendelse av aktivert vann av denne type
GB9509844D0 (en) Screening for inhibitors of TCR-MHC interactions

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20061130